Advance of several types of important marine antitumor drugs

Yaoxue Xuebao

Volumn 43, Issue 5, 2008, Pages 435-442

  Zhang, Jian Ye ^a   Fu, Li Wu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Antitumor drug; Marine natural product; Progress

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; BRYOSTATIN; BRYOSTATIN 1; DEPSIPEPTIDE; DIDEMNINS; DISULFIDE; DOLASTATIN 10; DRUG DERIVATIVE; ETHER DERIVATIVE; HALICHONDRIN B; PSAMMAPLIN A; TETRAHYDROISOQUINOLINE DERIVATIVE; TRABECTEDIN; TYROSINE;

ANIMAL; APOPTOSIS; ARTICLE; BIOLOGY; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL PRODUCTS; BRYOSTATINS; CELL LINE, TUMOR; DEPSIPEPTIDES; DIOXOLES; DISULFIDES; ETHERS, CYCLIC; HUMANS; MARINE BIOLOGY; NEOPLASMS; TETRAHYDROISOQUINOLINES; TYROSINE;

EID: 47249109404     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Sun MK, Alkon DL. Bryostatin-1; pharmacology and therapeutic potential as a CNS drug [J]. CNS Drug Rev, 2006,12:1-8.
2. Sun MK, Alkon DL. Dual effects of bryostatin-1 on spatial memory and depression [J]. Eur J Pharmacol, 2005,512:43-51.
3. Kortmansky J , Schwartz GK. Bryostatin-1: a novel PKC inhibitor in clinical development [J]. Cancer Invest, 2003,21:924-936.
4. Hayun M, Okun E, Hayun R, et al. Synergistic effect of AS101 and bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model [J]. Leukemia, 2007,21:1504-1513.
5. Choi SH, Hyman T, Blumberg PM. Differential effect of bryostatin 1 and phorbol 12-myristate 13-acetate on HOP-92 cell proliferation is mediated by down-regulation of protein kinase Cdelta [J]. Cancer Res, 2006, 66: 7261-7269.
6. Wall NR, Mohammad RM, Al-Katib AM. Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh [J]. Cell Growth Differ, 2001, 12:641 -647.
7. Roddie PH, Horton Y, Turner ML. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1 [J]. Leukemia, 2002,16:84-93.
8. Clark CS, Konyer JE, Meckling KA. 1alpha, 25-Dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression [J]. Exp Cell Res, 2004,294:301-311.
9. Wang Z, Wang S, Dai Y, et al. Bryostatin 1 increases 1-beta-D- arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L) [J]. J Pharmacol Exp Ther, 2002, 301:568-577.
10. Mohanty S, Huang J, Basu A. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1 [J]. Clin Cancer Res, 2005, 1: 6730 - 6737.
11. Garcia CS, Curiel RE, Mwatibo JM, et al. The antineoplastic agent bryostatin-1 differentially regulates IFN-gamma receptor subunits in monocytic cells; transcriptional and posttranscriptional control of IFN-gamma R2 [J]. J Immunol, 2006,177:2707-2716
12. Nezhat F, Wadler S, Muggia F, et al. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix; a New York Gynecologic Oncology Group study [J]. Gynecol Oncol, 2004,93:144-148.
13. Do Y, Mainali E, Nagarkatti PS, et al. Bryostatin-1 in combination with calcium ionophore promotes the maturation of human umbilical cord-blood monocyte-derived dendritic cells capable of activating neonatal alloreactive T cells [J]. Cell Immunol, 2004, 231:8-13.
14. Cragg LH, Andreeff M, Feldman E, et al. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-β-D-arabinofuranosylcytosine in patients with refractory acute leukemia [J]. Clin Cancer Res, 2002,8:2123-2133.
15. Marshall JL, Bangalore N, El-Ashry D, et al. Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies [J]. Cancer Biol Ther, 2002,1: 409-416.
16. Roberts JD, Smith MR, Feldman EJ, et al. Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma [J]. Clin Lymphoma, 2002,3:184-188.
17. Roberts JD, Smith MR, Feldman EJ, et al. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma [J]. Clin Cancer Res, 2006,12:5809-5816.
18. Ajani JA, Jiang Y, Faust J, et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 ( NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma [J]. Invest New Drugs, 2006,24:353-357.
19. El-Rayes BF, Gadgeel S, Shields AF, et al. Phase I study of bryostatin 1 and gemcitabine [J]. Clin Cancer Res, 2006,12:7059-7062.
20. Takebayashi Y, Goldwasser F, Urasaki Y, et al. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression [J]. Clin Cancer Res, 2001,7:185-191.
21. Moneo V, Serelde BG, Fominaya J, et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53 [J]. J Cell Biochem, 2007,100:339-348.
22. Friedman D, Hu Z, Kolb EA, et al. Ecteinascidin-743 inhibits activated but not constitutive transcription [J]. Cancer Res, 2002,62:3377-3381.
23. Marco E, García-Nieto R, Mendieta J, et al. A3. (ET743) -DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions [J]. J Med Chem, 2002,45:871-880.
24. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent [J]. Clin Cancer Res, 2001,7:2908-2911.
25. Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft tissue sarcomas [J]. Oncologist, 2005,10:827-832.
26. Scotlandi K, Perdichizzi S, Manara MC, et al. Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells [J]. Clin Cancer Res, 2002,8.-3893-3903.
27. Simmons TL, Andrianasolo E, McPhail K, et al. Marine natural products as anticancer drugs [J]. Mol Cancer Ther, 2005,4:333-342.
28. Kanzaki A, Takebayashi Y, Ren XQ, et al. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743 [J]. Mol Cancer Ther, 2002,1:1327 - 1334.
29. Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft-tissue sarcomas [J]. Curr Opin Oncol, 2006,18:347-353.
30. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer [J]. Br J Cancer, 2006,94:1610-1614.
31. Hoffman M, Blessing J, Lentz S. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study [J]. Gynecol Oncol, 2003,89:95-98.
32. Natsume T, Watanabe J, Koh Y, et al. Antitumor activity of TZT-1027 (soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo [J]. Cancer Sci, 2003,94:826-833.
33. Cruz-Monserrate Z, Mullaney J, Harran P, et al. Dolastatin 15 binds in the Vinca domain of tubulin as demonstrated by hummel-dreyer chromatography [J]. Eur J Biochem, 2003,270:3822-3828.
34. Ray A, Okouneva T, Manna T, et al. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate [J]. Cancer Res, 2007, 67:3767-3776.
35. Newman DJ, Cragg GM. Marine natural products and related compounds in clinical and advanced preclinical trials [J]. J Nat Prod, 2004,67:1216-1238.
36. Sings HL, Rinehart KL. Compounds produced from potential tunicate-blue-green algal symbiosis [J]. J Ind Microbiol Biotechnol, 1996,17:385-396.
37. Erba E, Serafini M , Gaipa G, et al. Effect of aplidin in acute lymphoblastic leukaemia cells [J]. Br J Cancer, 2003,89:763-773.
38. Broggini M, Marchini SV, Galliera E, et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4 [J]. Leukemia, 2003,17:52-59.
39. Jimeno J, Faircloth G, Fernandez Souse-Faro JM, et al. New marine derived anticancer therapeutics; a journey from the sea to clinical trials [J]. Marine Drugs, 2004, 2.14-29.
40. Amador ML, Jimeno J, Paz-Ares L, et al. Progress in the development and acquisition of anticancer agents from marine sources [J]. Ann Oncol, 2003,14-1607-1615.
41. Maroun JA, Belanger K, Seymour L, et al. Phase I study of aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study; NCIC CTG IND 115 [J]. Ann Oncol, 2006,17:1371-1378.
42. Pifia IC, Gautschi JT, Wang GY, et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase [J]. J Org Chem, 2003,68:3866-3873.
43. Shim JS, Lee HS, Shin J, et al. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro [J]. Cancer Lett, 2004, 203:163-169.
44. Remiszewski SW. The discovery of NVP-LAQ824; from concept to clinic [J]. Curr Med Chem, 2003,10:2393-2402.
45. Bai RL, Paull KD, Herald CL, et al. Halichondrin B and homohalichondrin B, marine natural products binding in the Vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data [J]. J Biol Chem, 1991,266:15882-15889.
46. Dabydeen D, Florence G, Paterson I, et al. A quantitative evaluation of the effects of inhibitors of tubulin assembly on polymerization induced by discodermolide, epothilone B, and paclitaxel [J]. Cancer Chemother Pharmacol, 2004,53:397-403.
47. Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin [J]. Mol Pharmacol, 2006,70:1866-1875.
48. Zhang JY, Wu HY, Xia XK, et al. Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathway [J]. Cancer Biol Ther. 2007,6:1413-1421.
49. Xia XK, Huang HR, She ZG, et al. Structural and biological properties of vermistatin and two new vermistatin derivatives isolated from the marine-mangrove endophytic fungus guignardia sp. No 4382 [J]. Helv Chim Acta, 2007,90:1925-1931.
50. Shi Z, Jain S, Kim IW, et al. Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1) -mediated multidrug resistance in cancer cells [J]. Cancer Sci. 2007,98:1373-1380.